Alexion Pharmaceuticals (NASDAQ:ALXN) Rating Lowered to Hold at BidaskClub

Alexion Pharmaceuticals (NASDAQ:ALXN) was downgraded by research analysts at BidaskClub from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Tuesday, BidAskClub reports.

Several other equities analysts have also issued reports on ALXN. Wedbush set a $190.00 price objective on Home Depot and gave the stock a “hold” rating in a report on Wednesday, May 22nd. Guggenheim reissued a “neutral” rating and set a $325.00 price target on shares of Biogen in a report on Thursday, March 21st. Goldman Sachs Group raised Lenovo Group from a “neutral” rating to a “buy” rating in a report on Thursday, May 23rd. They noted that the move was a valuation call. Raymond James set a $33.00 price target on LKQ and gave the stock a “buy” rating in a report on Friday, April 26th. Finally, Zacks Investment Research lowered Hammerson from a “hold” rating to a “sell” rating in a report on Friday, May 24th. One analyst has rated the stock with a sell rating, six have issued a hold rating and thirteen have given a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus target price of $161.06.

Shares of ALXN stock traded down $2.88 during mid-day trading on Tuesday, hitting $121.49. 1,576,169 shares of the stock were exchanged, compared to its average volume of 1,520,079. The firm’s fifty day moving average price is $124.07. The company has a market capitalization of $28.58 billion, a PE ratio of 17.14, a price-to-earnings-growth ratio of 0.98 and a beta of 1.64. Alexion Pharmaceuticals has a 12-month low of $92.56 and a 12-month high of $141.86. The company has a quick ratio of 3.36, a current ratio of 3.87 and a debt-to-equity ratio of 0.25.

Alexion Pharmaceuticals (NASDAQ:ALXN) last issued its quarterly earnings data on Thursday, April 25th. The biopharmaceutical company reported $2.39 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.99 by $0.40. The company had revenue of $1.14 billion for the quarter, compared to analyst estimates of $1.13 billion. Alexion Pharmaceuticals had a return on equity of 19.53% and a net margin of 9.59%. The business’s quarterly revenue was up 22.5% compared to the same quarter last year. During the same quarter last year, the company posted $1.68 earnings per share. As a group, analysts anticipate that Alexion Pharmaceuticals will post 8.61 earnings per share for the current year.

In related news, EVP Indrani Lall Franchini sold 4,500 shares of the firm’s stock in a transaction dated Monday, July 1st. The shares were sold at an average price of $132.78, for a total value of $597,510.00. Following the completion of the sale, the executive vice president now owns 29,627 shares in the company, valued at $3,933,873.06. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Bros. Advisors Lp Baker sold 123,489 shares of the firm’s stock in a transaction dated Tuesday, May 28th. The shares were sold at an average price of $126.53, for a total transaction of $15,625,063.17. The disclosure for this sale can be found here. In the last three months, insiders have sold 428,567 shares of company stock worth $53,420,869. Corporate insiders own 4.08% of the company’s stock.

Large investors have recently made changes to their positions in the stock. Investors Research Corp acquired a new stake in Alexion Pharmaceuticals in the first quarter valued at about $27,000. Captrust Financial Advisors acquired a new stake in Alexion Pharmaceuticals in the fourth quarter valued at about $31,000. Thor Advisors LLC acquired a new stake in Alexion Pharmaceuticals in the first quarter valued at about $34,000. Berman Capital Advisors LLC lifted its position in Alexion Pharmaceuticals by 68.6% in the first quarter. Berman Capital Advisors LLC now owns 322 shares of the biopharmaceutical company’s stock valued at $42,000 after purchasing an additional 131 shares during the period. Finally, Institutional & Family Asset Management LLC lifted its position in shares of Alexion Pharmaceuticals by 39.5% during the 1st quarter. Institutional & Family Asset Management LLC now owns 307 shares of the biopharmaceutical company’s stock valued at $42,000 after acquiring an additional 87 shares during the period. Hedge funds and other institutional investors own 94.42% of the company’s stock.

About Alexion Pharmaceuticals

Alexion Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and Soliris (eculizumab), a monoclonal antibody for the treatment of PNH, atypical hemolytic uremic syndrome (aHUS), and generalized myasthenia gravis.

Further Reading: Liquidity

Analyst Recommendations for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.